DSpace Repository

Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin

Show simple item record

dc.contributor.author Parlakpinar, H.
dc.contributor.author Polat, S.
dc.contributor.author Acet, H.A.
dc.date.accessioned 2022-10-06T12:50:04Z
dc.date.available 2022-10-06T12:50:04Z
dc.date.issued 2021
dc.identifier.issn 07673981 (ISSN)
dc.identifier.uri http://hdl.handle.net/11616/71646
dc.description.abstract Coronavirus disease 2019 (COVID-19) is a life-threatening infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 pandemic causing morbidities and even deaths worldwide revealed that there is urgent need to find pharmacological agents or vaccines. Although there are a lot of agents under investigation, there is no approved agent for the prevention or treatment of the COVID-19 yet. Treatment of patients remains mainly supportive as well as compassionate use of the agents under investigation. It is well established that excessive inflammatory and immune response and oxidative injury play a critical role in the pathogenesis of COVID-19. In this review, we aimed to update knowledge about pathogenesis, clinical features, and pharmacological treatment of COVID-19 and review the potential beneficial effects of ancient antioxidant, anti-inflammatory, and immunomodulatory molecule melatonin for prevention and treatment of COVID-19. © 2020 Société Française de Pharmacologie et de Thérapeutique.
dc.source Fundamental and Clinical Pharmacology
dc.title Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record